A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Aaron Lisberg(University of California, Los Angeles), Amy L. Cummings(University of California, Los Angeles), Jonathan W. Goldman(University of California, Los Angeles), Krikor Bornazyan(University of California, Los Angeles), Nicholas Reese(University of California, Los Angeles), T. Wang(University of California, Los Angeles), Paul Coluzzi(University of California, Los Angeles), Blanca Ledezma(University of California, Los Angeles), Melody Mendenhall(University of California, Los Angeles), J.S. Hunt(University of California, Los Angeles), Brian R. Wolf(University of California, Los Angeles), Benjamin Jones(University of California, Los Angeles), John Madrigal(University of California, Los Angeles), John M. Horton(University of California, Los Angeles), Marshall L. Spiegel(University of California, Los Angeles), James Carroll(University of California, Los Angeles), Jaklin Gukasyan(University of California, Los Angeles), T.J. Williams(University of California, Los Angeles), L. Sauer(University of California, Los Angeles), Courtney Wells(University of California, Los Angeles), Ariana Hardy(University of California, Los Angeles), Paulina Linares(University of California, Los Angeles), Chong-Hee Lim(University of California, Los Angeles), Lin Ma(University of California, Los Angeles), Carlos Adame(University of California, Los Angeles), Edward B. Garon(University of California, Los Angeles)
Cited by 588Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis